Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14830112 | 0.86 | CTSK (0.35) | PRKACAPRKACGPRKACBCTSKMETTL3 | |
| Trifluoroacetic Acid SCHEMBL14829358 | 0.82 | PRKACA (0.43) | PRKACAPRKACGPRKACBCTSKPARP1 | |
| SCHEMBL14829511 | 0.81 | PRKACA (0.42) | PRKACAPRKACGPRKACBCTSKTMEM97 | |
| SCHEMBL14839512 | 0.79 | PRKACA (0.48) | PRKACAPRKACGPRKACBCTSKPARP1 | |
| Trifluoroacetic Acid SCHEMBL14829510 | 0.76 | PRKACA (0.44) | PRKACAPRKACGPRKACBCTSKKDM1A | |
| Trifluoroacetic Acid SCHEMBL14829349 | 0.75 | KDM1A (0.44) | PRKACAPRKACGPRKACBCTSKTACR1 | |
| SCHEMBL14837281 | 0.73 | CTSK (0.36) | PRKACAPRKACGPRKACBCTSKMETTL3 | |
| SCHEMBL26084666 | 0.72 | HTR1A (0.51) | PRKACAPRKACGPRKACBTACR1KDM1A | |
| SCHEMBL26084665 | 0.72 | HTR1A (0.51) | PRKACAPRKACGPRKACBTACR1KDM1A | |
| SCHEMBL432870 | 0.70 | PRKACA (0.52) | PRKACAPRKACGPRKACBCTSKMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751088-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2751088-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8765751-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013049719-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, PLK1 | PRKACA 159/4885PRKACG 225/4885PRKACB 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.